Conference Coverage

Second trimester fetal loss: Shared decision-making, patient preference are key


 

EXPERT ANALYSIS FROM ACOG 2019

  • Anesthesia, which is local plus intravenous sedation for surgery, compared with IV narcotics and potentially an epidural or other type of regional anesthesia for medical management.
  • Duration, which is 5-20 minutes for surgery, compared with 6-11 hours with mifepristone + misoprostol, and up to 20 hours with misoprostol alone.
  • Location, which is done on an outpatient basis for surgery, compared with inpatient care for medical management.
  • Cost, which is $1,000-$5,000 for surgery vs. $3,000-$9,000 for medical management.
  • Contact with the fetus, which typically involves the possibility of partial viewing and an opportunity to obtain footprints as a memento if an intact procedure is attempted during surgery vs. full viewing and possibly holding the baby after delivery following medical management. This is often the key deciding factor for patients.
  • Provider factors, in terms of training and skills. Surgery involves a need for specialized training, whereas medical management requires no extra training, she said, adding that “not all ob.gyns. across the country are competent or comfortable providing a D&E, particularly in the later second-trimester time period.” However, the availability of family planing fellowships will increase the number of centers across the country where both options will be available, she noted.
  • The possibility of fetal autopsy, which surgery often (but not always) allows, but medical management always allows.
  • Involvement level, which is provider heavy for surgery vs. patient heavy for medical management.

“Moving toward an evidence-based, patient-centered care model requires a lot of us, as providers, to really work at dropping our assumptions. We often have strong opinions about what we think we would do in that setting, and it can be tricky for us to set that aside and allow patients to really ask questions and discuss their values so that we can then advocate best for our patients after they know exactly what their options are,” she said.

Dr. Prager reported having no relevant disclosures.

Pages

Recommended Reading

First-time fathers at risk of postnatal depressive symptoms
MDedge ObGyn
Expert advice for immediate postpartum LARC insertion
MDedge ObGyn
Little association found between in utero H1N1 vaccine and 5-year health outcomes
MDedge ObGyn
iPledge: Fetal exposure to isotretinoin continues
MDedge ObGyn
USPSTF updates, reaffirms recommendation for HBV screening in pregnant women
MDedge ObGyn
New WHO recommendations promote dolutegravir benefits in the face of lowered risk signal for neural tube defects
MDedge ObGyn
Clinics get more time on Title X changes
MDedge ObGyn
Postpartum care: State scorecard for Medicaid enrollees
MDedge ObGyn
U.S. fertility rate, teen births are on the decline
MDedge ObGyn
Fetal alcohol exposure overlooked again?
MDedge ObGyn